EDP 420

Drug Profile

EDP 420

Alternative Names: EDP-420; EP-013420; EP-13420; S-013420

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer Enanta Pharmaceuticals; Shionogi
  • Class Antibacterials; Macrolides; Organic bridged compounds
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Helicobacter infections; Mycobacterium avium complex infections; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis

Most Recent Events

  • 25 May 2010 Discontinued - Phase-II for Respiratory tract infections in Japan (PO)
  • 28 Oct 2008 Preclinical trials in Skin and soft tissue infections in USA (PO)
  • 28 Oct 2008 Preclinical pharmacodynamics data presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top